United Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics acquired Thymmune Therapeutics for $140 million in cash, with an additional $160 million in potential earn-outs contingent on clinical milestones through 2031. The transaction adds Thymmune's proprietary iPSC-derived thymic cell platform to UTHR's portfolio, complementing the existing UThymoKidney program aimed at transplant tolerance.
Key figures
- Deal Value Usd
- 140000000
- Drug Name
- THY-100
- Earn out max
- 160000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.